28bio

28bio is a startup based in Metairie, the United States. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

28bio develops human-derived brain and peripheral nerve organoid platforms (Brain-on-a-Chip and Nerve-on-a-Chip) and delivers associated services to enable neurotoxicity, efficacy, and disease modeling for pharmaceutical research. Their CNS-3D and PNS-3D products provide functional assays for seizure liability, neuroinflammation, myelination, and Alzheimer’s disease.